All In Biotech

Drug Trial Radar · NCT01976104

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

204

Actual

Start

Nov 2013

Primary completion

Jan 30, 2017

Study completion Feb 21, 2017

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Nov 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for platelet transfusions or any rescue procedure for bleeding due to procedural and post-procedural bleeding complications. Participants will be enrolled into 2 cohorts according to mean baseline platelet count and, within each baseline platelet count cohort will be further stratified by risk of bleeding associated with the elective procedure (low, moderate, or high) and hepatocellular carcinoma (HCC) status (Yes or No).

Conditions

  • Thrombocytopenia Associated With Liver Disease

Interventions

  • avatrombopag (lower baseline platelet count)Drug

    60 mg avatrombopag (3 x 20 mg tablets)

  • placebo (lower baseline platelet count)Drug

    60 mg placebo (3 x 20 mg matching placebo tablets)

  • avatrombopag (higher baseline platelet count)Drug

    40 mg avatrombopag (2 x 20 mg tablets)

  • placebo (higher baseline platelet count)Drug

    40 mg placebo (2 x 20 mg matching placebo tablets)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled ProcedureTime frame: Randomization (Visit 2), up to 7 Days following a scheduled procedure

Locations

120 sites in 17 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Coronado, California

  • Site not named

    Loma Linda, California

  • Site not named

    Denver, Colorado

  • Site not named

    Miami, Florida

  • Site not named

    Maywood, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Kansas City, Kansas

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Kansas City, Missouri

  • Site not named

    New York, New York

  • Site not named

    Statesville, North Carolina

  • Site not named

    Charleston, South Carolina

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Ciudad Autonoma Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Rosario, Argentina

  • Site not named

    Clayton, Victoria, Australia

  • Site not named

    Footscray, Victoria, Australia

  • Site not named

    Melbourne, Victoria, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Aracaju, Brazil

  • Site not named

    Botucatu, Brazil

  • Site not named

    Porto Alegre, Brazil

  • Site not named

    Salvador, Brazil

  • Site not named

    Calgary, Canada

  • Site not named

    Edmonton, Canada

  • Site not named

    Hefei, Anhui, China

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.